Get access

Desferrioxamine treatment of porphyria cutanea tarda in a patient with HIV and chronic renal failure

Authors

  • Pedro Vasconcelos,

    Corresponding author
    1. Dermatology University Clinic, Hospital de Santa Maria, Serviço de Dermatologia, Lisboa, Portugal
    • Address correspondence and reprint requests to: Pedro Vasconcelos, MD, Dermatology resident, Dermatology University Clinic, Hospital de Santa Maria, Serviço de Dermatologia, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal, or email: jp_vasconcelos@hotmail.com.

    Search for more papers by this author
  • H. Luz-Rodrigues,

    1. Nephrology University Clinic, Hospital de Santa Maria, Serviço de Dermatologia, Lisboa, Portugal
    Search for more papers by this author
  • Carla Santos,

    1. Infectious Diseases University Clinic, Hospital de Santa Maria, Serviço de Dermatologia, Lisboa, Portugal
    Search for more papers by this author
  • Paulo Filipe

    1. Dermatology University Clinic, Hospital de Santa Maria, Serviço de Dermatologia, Lisboa, Portugal
    Search for more papers by this author

Abstract

Porphyria cutanea tarda (PCT) can occur in HIV patients. Current evidence suggests that HIV infection may interfere with the hepatic cytochrome oxidase system, leading to porphyrin metabolism impairment. Moreover, chronic hemodialysis in renal failure may be a risk factor for PCT. In addition to the contributory factors for PCT associated to HIV infection, it is possible that porphyrin accumulation secondary to renal failure may play a role in the expression of this disease. We report a case of PCT in an HIV-1 infected patient under blood dialysis, refractory to antimalarials and controlled with desferrioxamine.

Get access to the full text of this article

Ancillary